CL2007003491A1 - Forma cristalina del acido (3s)-3-[n-(n-(2-tercbutilfenil)oxamil)alaninil]amino-5(23,5,6-tetrafluorofenoxi)-4-oxopentanoico; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar la fibrosis hepatica. - Google Patents
Forma cristalina del acido (3s)-3-[n-(n-(2-tercbutilfenil)oxamil)alaninil]amino-5(23,5,6-tetrafluorofenoxi)-4-oxopentanoico; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar la fibrosis hepatica.Info
- Publication number
- CL2007003491A1 CL2007003491A1 CL200703491A CL2007003491A CL2007003491A1 CL 2007003491 A1 CL2007003491 A1 CL 2007003491A1 CL 200703491 A CL200703491 A CL 200703491A CL 2007003491 A CL2007003491 A CL 2007003491A CL 2007003491 A1 CL2007003491 A1 CL 2007003491A1
- Authority
- CL
- Chile
- Prior art keywords
- tetrafluorofenoxi
- tercbutilfenil
- oxopentanoico
- alaninil
- oxamil
- Prior art date
Links
- 206010019668 Hepatic fibrosis Diseases 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- KZAUOCCYDRDERY-UHFFFAOYSA-N oxamyl Chemical compound CNC(=O)ON=C(SC)C(=O)N(C)C KZAUOCCYDRDERY-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86874806P | 2006-12-06 | 2006-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007003491A1 true CL2007003491A1 (es) | 2008-06-20 |
Family
ID=39205161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200703491A CL2007003491A1 (es) | 2006-12-06 | 2007-12-04 | Forma cristalina del acido (3s)-3-[n-(n-(2-tercbutilfenil)oxamil)alaninil]amino-5(23,5,6-tetrafluorofenoxi)-4-oxopentanoico; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar la fibrosis hepatica. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7692038B2 (es) |
| EP (1) | EP2091910B1 (es) |
| JP (1) | JP5495787B2 (es) |
| KR (1) | KR101125932B1 (es) |
| CN (3) | CN103951583B (es) |
| AR (1) | AR064809A1 (es) |
| AU (1) | AU2007330478B2 (es) |
| CA (1) | CA2669849C (es) |
| CL (1) | CL2007003491A1 (es) |
| DK (1) | DK2091910T3 (es) |
| ES (1) | ES2524021T3 (es) |
| HK (3) | HK1138567A1 (es) |
| HN (1) | HN2007000536A (es) |
| IL (1) | IL198732A (es) |
| MX (1) | MX2009006055A (es) |
| NO (1) | NO338908B1 (es) |
| PA (1) | PA8759501A1 (es) |
| PE (1) | PE20081251A1 (es) |
| PL (1) | PL2091910T3 (es) |
| PT (1) | PT2091910E (es) |
| TW (1) | TWI345466B (es) |
| UY (1) | UY30758A1 (es) |
| WO (1) | WO2008068615A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3150610T3 (da) * | 2010-02-12 | 2019-11-04 | Pfizer | Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on |
| CN103113405B (zh) * | 2012-10-17 | 2016-03-02 | 上海日馨生物科技有限公司 | 苯磷硫胺多晶型体、制备方法及其应用 |
| KR20220070066A (ko) * | 2014-03-14 | 2022-05-27 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
| ES2751652T3 (es) | 2014-05-12 | 2020-04-01 | Conatus Pharmaceuticals Inc | Tratamiento con inhibidor de caspasa emricasan de las complicaciones por las enfermedades hepáticas crónicas |
| EP4349406A3 (en) * | 2014-09-08 | 2024-05-22 | Pfizer Inc. | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament |
| US9676746B2 (en) | 2015-01-30 | 2017-06-13 | Biomed Valley Discoveries, Inc. | Crystalline forms of C21H22Cl2N4O2 |
| US20180044375A1 (en) | 2015-03-06 | 2018-02-15 | Concert Pharmaceuticals, Inc. | Deuterated emricasan |
| CN105017061B (zh) * | 2015-07-07 | 2017-03-29 | 苏州富士莱医药股份有限公司 | 一种恩利卡生的合成方法 |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| WO2017117478A1 (en) | 2015-12-31 | 2017-07-06 | Conatus Pharmaceuticals Inc. | Methods of using caspase inhibitors in treatment of liver disease |
| BR112019005985A2 (pt) | 2016-10-05 | 2019-06-25 | Novartis Ag | composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico |
| WO2018133870A1 (zh) * | 2017-01-23 | 2018-07-26 | 正大天晴药业集团股份有限公司 | 作为Caspase抑制剂的联环化合物 |
| WO2018172950A1 (en) * | 2017-03-23 | 2018-09-27 | Novartis Ag | Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate |
| WO2018178129A1 (en) * | 2017-03-30 | 2018-10-04 | Merck Patent Gmbh | Crystalline form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol |
| AR114251A1 (es) * | 2018-02-13 | 2020-08-12 | Syngenta Participations Ag | Formas cristalinas de n-[2-(2,4-diclorofenil)ciclobutil]-2-(trifluorometl)piridin-3-carboxamida |
| CA3105352A1 (en) | 2018-06-29 | 2020-01-02 | Histogen, Inc. | (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases |
| JP2022524049A (ja) | 2019-03-07 | 2022-04-27 | クオナトウス ファーマシューティカルズ，インコーポレイテッド | カスパーゼ阻害剤及びその使用方法 |
| CN111351780A (zh) * | 2019-12-29 | 2020-06-30 | 中船重工（邯郸）派瑞特种气体有限公司 | 一种三氟甲基磺酰氟电解槽中电解液成分的分析方法 |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69217762T2 (de) * | 1991-07-30 | 1997-10-09 | Ajinomoto Kk | Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung |
| DE59307210D1 (de) * | 1993-05-12 | 1997-10-02 | Heumann Pharma Gmbh & Co | Stabile und kristalline Form von Bezafibrat |
| US6544951B2 (en) * | 1998-07-02 | 2003-04-08 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US7053056B2 (en) * | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6197750B1 (en) * | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| GB9923933D0 (en) * | 1999-10-08 | 1999-12-08 | Smithkline Beecham Lab | Novel pharmaceutical |
| DK1462439T3 (da) * | 2001-12-11 | 2008-04-21 | Kyorin Seiyaku Kk | Hidtil ukendte stabile krystaller af substitueret phenylpropionsyrederivat og fremgangsmåder til fremstilling af den samme |
| CN101217980A (zh) * | 2005-07-11 | 2008-07-09 | 辉瑞有限公司 | 治疗肝纤维化的抗madcam抗体和抗纤维化半胱天冬蛋白酶抑制剂的新组合 |
-
2007
- 2007-12-03 PT PT78590338T patent/PT2091910E/pt unknown
- 2007-12-03 KR KR1020097011692A patent/KR101125932B1/ko active IP Right Grant
- 2007-12-03 CN CN201410058519.5A patent/CN103951583B/zh active Active
- 2007-12-03 JP JP2009539823A patent/JP5495787B2/ja active Active
- 2007-12-03 CN CN200780045311.8A patent/CN101573328B/zh active Active
- 2007-12-03 WO PCT/IB2007/003900 patent/WO2008068615A1/en active Application Filing
- 2007-12-03 AU AU2007330478A patent/AU2007330478B2/en active Active
- 2007-12-03 PL PL07859033T patent/PL2091910T3/pl unknown
- 2007-12-03 MX MX2009006055A patent/MX2009006055A/es active IP Right Grant
- 2007-12-03 DK DK07859033.8T patent/DK2091910T3/en active
- 2007-12-03 ES ES07859033.8T patent/ES2524021T3/es active Active
- 2007-12-03 CN CN201410057544.1A patent/CN103923169B/zh not_active Expired - Fee Related
- 2007-12-03 EP EP07859033.8A patent/EP2091910B1/en active Active
- 2007-12-03 CA CA2669849A patent/CA2669849C/en active Active
- 2007-12-04 PA PA20078759501A patent/PA8759501A1/es unknown
- 2007-12-04 CL CL200703491A patent/CL2007003491A1/es unknown
- 2007-12-04 HN HN2007000536A patent/HN2007000536A/es unknown
- 2007-12-04 UY UY30758A patent/UY30758A1/es not_active Application Discontinuation
- 2007-12-05 PE PE2007001720A patent/PE20081251A1/es not_active Application Discontinuation
- 2007-12-05 TW TW096146304A patent/TWI345466B/zh active
- 2007-12-05 AR ARP070105447A patent/AR064809A1/es not_active Application Discontinuation
- 2007-12-06 US US11/951,801 patent/US7692038B2/en active Active
-
2009
- 2009-05-13 IL IL198732A patent/IL198732A/en active IP Right Grant
- 2009-05-14 NO NO20091892A patent/NO338908B1/no not_active IP Right Cessation
-
2010
- 2010-05-03 HK HK10104322.9A patent/HK1138567A1/xx not_active IP Right Cessation
-
2015
- 2015-01-07 HK HK15100168.9A patent/HK1199885A1/xx unknown
- 2015-01-23 HK HK15100810.1A patent/HK1200440A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007003491A1 (es) | Forma cristalina del acido (3s)-3-[n-(n-(2-tercbutilfenil)oxamil)alaninil]amino-5(23,5,6-tetrafluorofenoxi)-4-oxopentanoico; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar la fibrosis hepatica. | |
| BRPI0816553A2 (pt) | "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto" | |
| CL2007001972A1 (es) | Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos. | |
| CL2009000882A1 (es) | Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer. | |
| BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
| CL2007001759A1 (es) | Compuesto metformina r-(+) lipoato; mezcla que comprende metformina y acido r-(+) lipoico; composicion farmaceutica que comprende el compuesto; metodo para preparar el compuesto; kit; y uso para tratar la diabetes. | |
| CL2007002446A1 (es) | Compuestos derivados de morfolino pirimidina; composicion farmaceutica; y su uso para preparar un medicamento para producir un efecto antiproliferante. | |
| BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
| CL2008000197A1 (es) | Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
| CL2008000094A1 (es) | Compuestos derivados de pteridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para aumentar la vasodilatacion. | |
| CL2007001325A1 (es) | Compuestos derivados de biciclos, inhibidores de cept; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, entre otras enfermedades. | |
| CL2007003423A1 (es) | Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda | |
| MA30236B1 (fr) | Nouvelle composition pharmaceutique | |
| CL2008001002A1 (es) | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. | |
| CL2007002916A1 (es) | Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras. | |
| BRPI0809667A2 (pt) | Composto, medicamento e composição farmacêutica que o contém e uso do composto | |
| CL2007003232A1 (es) | Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas. | |
| CL2008000784A1 (es) | Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co | |
| BRPI0912539A2 (pt) | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. | |
| CL2007002021A1 (es) | Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias. | |
| BRPI0814821A2 (pt) | Composto, composição farmacêutica, e, processo para preparar um composto | |
| BRPI0815360A2 (pt) | Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto | |
| BRPI0816916A2 (pt) | Formulações e dispositivos para liberação de compostos a artrópodes e microorganismos no interior dos mesmos. | |
| CL2008000408A1 (es) | Compuestos derivados de pirrolidin-amida inhibidores de la proteasa activadora de canal; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar fibrosis quistica, bronquitis cronica, cancer de pulmon entre otras enfermedades | |
| CL2008000585A1 (es) | Compuestos derivados de nicotinamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada por prostaglandina d2 producida por h-pgds. |